Your Genes Determine How Your Body Processes CBD — and Its Side Effects

What the researchers found

CYP2C19 metabolizer status significantly affected CBD exposure, with lower CBD levels in intermediate metabolizers (p=0.014 single dose, p=0.003 steady state). Individuals with both CYP3A5 poor metabolism and CYP2C19 intermediate/normal metabolism had increased active metabolite exposure and experienced diarrhea 5.6x more frequently (39% vs. 7%, p=0.046).

Why it matters

With millions using CBD products, understanding why some people experience side effects while others don't is crucial. This study shows genetics play a major role — opening the door to pharmacogenomic-guided CBD dosing and better prediction of drug interactions.

The numbers in context

33 healthy subjects. CBD 5mg/kg single dose then 5mg/kg BID x14 days. Diarrhea: 39% in CYP3A5 poor + CYP2C19 intermediate/normal vs. 7% others (p=.046). CYP2C19 intermediate metabolizers: lower CBD exposure (p=.014 single, p=.003 steady state). External cohort validated CYP2C19 findings.

How the study worked

Secondary analysis of open-label, fixed-sequence, single-center study. 33 healthy subjects received single-dose CBD 5mg/kg then titrated to 5mg/kg twice daily for 14 days. CYP3A, CYP2C9, and CYP2C19 genotypes assessed. Pharmacokinetic parameters by noncompartmental analysis. External validation cohort confirmed CYP2C19 findings.

What this study cannot tell us

Small sample (33 subjects). Healthy volunteers may differ from patients. Single formulation and dosing regimen. Not all CYP genotype combinations well-represented. Open-label design.

How to read the evidence

Small but well-designed pharmacogenomic study with external validation — strong mechanistic evidence though clinical application needs larger trials.

When this study was published

Published in 2026, advancing pharmacogenomic understanding of CBD metabolism.

The bigger picture

This is the beginning of personalized cannabinoid medicine. Just as genetic testing guides dosing for drugs like warfarin and clopidogrel, CBD dosing may eventually be tailored to an individual's genetic profile to maximize benefit and minimize side effects.

Questions still open

• Should genetic testing be recommended before high-dose CBD use? Would genotype-guided dosing reduce side effects in epilepsy patients on Epidiolex? Can pharmacogenomics predict CBD-drug interactions?

Common questions

Read the original research

Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers.

Clinical and translational science, 19(1), e70455

Citation

Etkins, Jumar; So, Gerald C; Lu, Jessica Bo Li; Koyama, Sachiko; Gisch, Debora L; Melo Ferreira, Ricardo; Cheng, Ying-Hua; McClara, Kelsey; Jun, Joshua; Miller, Matthew; Desta, Zeruesenay; Eadon, Michael T. (2026). Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers.. Clinical and translational science, 19(1), e70455. https://doi.org/10.1111/cts.70455

Explore the wider topic

• CBD Oil Quality Guide: How to Avoid Snake Oil
• Anxiety After Quitting Weed: When to Consider Medication
• Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
• Cannabis for Chronic Pain: What the Research Actually Supports
• Cannabis and Epilepsy: The Epidiolex Story and What It Means
• Does CBD Actually Work for Anxiety? What the Evidence Shows
• Does CBD Help with Weed Withdrawal? What Studies Show
• CBD vs THC: The Differences That Actually Matter
• The Proven Medical Benefits of Cannabis: What Research Supports
• Quitting Weed Before Surgery
• Weed and Medications: What Changes When You Quit
• Quitting Weed During Pregnancy: What You Need to Know
• Quitting Weed While Pregnant: What You Need to Know
• Cannabis and Older Adults: Risks Seniors Should Know
• Cannabis and Breastfeeding: THC in Breast Milk